Ultrasound-detected dactylitis lesions may help identify patients with psoriasis who are at risk for psoriatic arthritis and ...

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

J&J has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in treating plaque psoriasis (PsO).

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow ...

Oruka Therapeutics, Inc.’s ORKA share price has surged by 6.65%, which has investors questioning if this is right time to sell.

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis: Spring House, Pennsylvania Monday, April 7 ...

South Korea’s Samsung Bioepis presented data, including the budget impact analysis on ustekinumab biosimilars’ cost savings ...

STEQEYMA is available in both subcutaneous injection and intravenous infusion and is indicated for the treatment of plaque psoriasis (PsO) and psoriatic arthritis (PsA) in adult and pediatric ...